FGFR4 and hepatocellular carcinoma: However, two resistant mutations in FGFR4 were detected after Fisogatinib treatment in HCC patients; LY2874455 designed targeting FGFR4 V550L can overcome Fisogatinib resistance in a mouse model [173].